CO2019013718A2 - Anticuerpos anti-trkb - Google Patents

Anticuerpos anti-trkb

Info

Publication number
CO2019013718A2
CO2019013718A2 CONC2019/0013718A CO2019013718A CO2019013718A2 CO 2019013718 A2 CO2019013718 A2 CO 2019013718A2 CO 2019013718 A CO2019013718 A CO 2019013718A CO 2019013718 A2 CO2019013718 A2 CO 2019013718A2
Authority
CO
Colombia
Prior art keywords
trkb antibodies
trkb
antibodies
therapeutic
compositions
Prior art date
Application number
CONC2019/0013718A
Other languages
English (en)
Inventor
Sanjaya Singh
Sarah Low
Vladimir Voynov
Rolf Herrmann
Remko Alexander Bakker
Sebastian Bandholtz
Peter Michael Benz
Michael Dziegelewski
Lore Florin
Cynthia Hess Kenny
Holger Rosenbrock
Heiko Friedrich Stahl
Sathyadevi Venkataramani
Haiguang Xiao
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CO2019013718A2 publication Critical patent/CO2019013718A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

La presente invención se refiere a anticuerpos agonistas anti-TrkB novedosos y métodos terapéuticos y de diagnóstico y composiciones para su uso.
CONC2019/0013718A 2017-06-09 2019-12-05 Anticuerpos anti-trkb CO2019013718A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17175122 2017-06-09
PCT/EP2018/065107 WO2018224630A1 (en) 2017-06-09 2018-06-08 Anti-trkb antibodies

Publications (1)

Publication Number Publication Date
CO2019013718A2 true CO2019013718A2 (es) 2020-01-17

Family

ID=59034551

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0013718A CO2019013718A2 (es) 2017-06-09 2019-12-05 Anticuerpos anti-trkb

Country Status (22)

Country Link
US (3) US10793634B2 (es)
EP (1) EP3635004A1 (es)
JP (2) JP7267208B2 (es)
KR (1) KR20200017421A (es)
CN (1) CN110719916A (es)
AR (1) AR112602A1 (es)
AU (1) AU2018279184A1 (es)
BR (1) BR112019023742A2 (es)
CA (1) CA3063965A1 (es)
CL (1) CL2019003557A1 (es)
CO (1) CO2019013718A2 (es)
EA (1) EA201992883A1 (es)
IL (1) IL271067B1 (es)
MA (1) MA49257A (es)
MX (1) MX2019014714A (es)
MY (1) MY202315A (es)
PE (1) PE20200173A1 (es)
PH (1) PH12019502694A1 (es)
SG (1) SG11201911814UA (es)
TW (2) TW202342100A (es)
UA (1) UA127967C2 (es)
WO (1) WO2018224630A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200013231A (ko) * 2017-06-02 2020-02-06 베링거 인겔하임 인터내셔날 게엠베하 항암 조합 요법
EP4232476A2 (en) 2020-10-21 2023-08-30 Boehringer Ingelheim International GmbH Agonistic trkb binding molecules for the treatment of eye diseases
WO2023125485A1 (en) * 2021-12-28 2023-07-06 4B Technologies (Beijing) Co., Limited TrkB ANTIBODY AND APPLICATION THEREOF

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
ATE135397T1 (de) 1988-09-23 1996-03-15 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP0752248B1 (en) 1992-11-13 2000-09-27 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
AU2006255101A1 (en) 2005-06-06 2006-12-14 Wyeth Anti-TrkB monoclonal antibodies and uses thereof
EP2087007A2 (en) * 2006-11-09 2009-08-12 Irm Llc Agonist trkb antibodies and uses thereof
RU2009123491A (ru) * 2006-12-20 2010-12-27 Ринат Ньюросайенс Корпорейшн (Us) АГОНИСТЫ TrkB ДЛЯ ЛЕЧЕНИЯ АУТОИММУННЫХ НАРУШЕНИЙ
CN101980603A (zh) * 2007-10-11 2011-02-23 比奥根艾迪克Ma公司 LINGO-1和TrkB拮抗剂的用途
JP2011501760A (ja) 2007-10-23 2011-01-13 ノバルティス アーゲー 呼吸器疾患の処置のためのｔｒｋｂ抗体の使用
BRPI0906877A2 (pt) 2008-01-17 2015-07-28 Irm Llc Anticorpos anti-trkb aperfeiçoados
PL2252633T3 (pl) 2008-02-04 2014-02-28 Lay Line Genomics Spa Przeciwciała anty-TrkA i ich pochodne
EP2318010A4 (en) 2008-07-28 2014-05-21 Univ Emory TREATMENT OF VARIOUS DISORDERS USING TRKB AGONISTS
WO2010086828A2 (en) * 2009-02-02 2010-08-05 Rinat Neuroscience Corporation Agonist anti-trkb monoclonal antibodies
WO2011103667A1 (en) * 2010-02-26 2011-09-01 6452728 Canada Inc. Agonistic antibodies to trkb receptors and uses thereof
WO2011156479A2 (en) 2010-06-09 2011-12-15 Emory University Trkb agonists and methods of use
US9200080B2 (en) 2010-09-03 2015-12-01 Horacio Uri Saragovi Agonistic antibodies to TrkC receptors and uses thereof
GB2491106A (en) 2011-05-18 2012-11-28 Univ Basel Antibodies against tropomyosin-related kinase B receptors
JP6868394B2 (ja) 2014-05-16 2021-05-12 ファイザー・インク 二重特異性抗体
JP7023461B2 (ja) 2015-07-28 2022-02-22 オトノミ―，インク． 耳の疾病の処置のためのｔｒｋｂ又はｔｒｋｃアゴニスト組成物及び方法
CN108350079B (zh) 2015-11-17 2021-11-02 葛兰素史密斯克莱知识产权发展有限公司 用于治疗神经学和其它病症的结合激动剂
WO2019108662A1 (en) 2017-11-30 2019-06-06 Regeneron Pharmaceuticals, Inc. Anti-trkb monoclonal antibodies and methods of use

Also Published As

Publication number Publication date
EA201992883A1 (ru) 2020-05-08
IL271067B1 (en) 2024-02-01
US20200399378A1 (en) 2020-12-24
IL271067A (en) 2020-01-30
UA127967C2 (uk) 2024-02-28
EP3635004A1 (en) 2020-04-15
MA49257A (fr) 2020-04-15
CL2019003557A1 (es) 2020-05-04
US20240101689A1 (en) 2024-03-28
BR112019023742A2 (pt) 2020-06-09
MY202315A (en) 2024-04-23
TWI808086B (zh) 2023-07-11
US11866501B2 (en) 2024-01-09
US20180355046A1 (en) 2018-12-13
US10793634B2 (en) 2020-10-06
AU2018279184A1 (en) 2019-11-21
WO2018224630A1 (en) 2018-12-13
PE20200173A1 (es) 2020-01-24
MX2019014714A (es) 2020-02-07
JP7267208B2 (ja) 2023-05-01
KR20200017421A (ko) 2020-02-18
AR112602A1 (es) 2019-11-20
SG11201911814UA (en) 2020-01-30
JP2023093621A (ja) 2023-07-04
CA3063965A1 (en) 2018-12-13
PH12019502694A1 (en) 2020-07-13
TW201920271A (zh) 2019-06-01
JP2020522270A (ja) 2020-07-30
CN110719916A (zh) 2020-01-21
TW202342100A (zh) 2023-11-01

Similar Documents

Publication Publication Date Title
CL2020001048A1 (es) Anticuerpos monoclonales contra bcma. (divisional solicitud 201800281)
CL2018000829A1 (es) Anticuerpos anti-cd19 humano con alta afinidad
CO2018010458A2 (es) Composiciones y anticuerpos anti-tim-3
CL2018000595A1 (es) Anticuerpos anti-pd1 y métodos de uso
ECSP17045736A (es) Composiciones y métodos para anticuerpos dirigidos a bmp6
CL2017000590A1 (es) Anticuerpos anti-cll-1 e inmunoconjugados
CL2017001408A1 (es) Anticuerpos anti-cd79b y métodos de uso
CR20180013A (es) Anticuerpos anti-tau y métodos de uso.
CL2016001871A1 (es) Anticuerpos humanos para pd-1
MA50505A (fr) Anticorps 2 + 1 bispécifiques (contorsbodies)
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
CR20150618A (es) Anticuerpos receptores de antitransferina y métodos de uso
BR112016018891A2 (pt) anticorpos anti-dll3 e conjugados de fármacos para uso em melanoma
CR20160362A (es) Anticuerpos anti-jagged1 y metodos de uso
PE20210648A1 (es) Anticuerpos anti-cd3 y metodos de uso
CR20150247A (es) Anticuerpos de antihemaglutinina y métodos de uso
BR112016025291A2 (pt) conjugados de anticorpo anti-ptk7-fármaco
BR112016014731A2 (pt) Anticorpos anti-baff
CL2020002540A1 (es) Anticuerpos anti-hla-g y utilización de los mismos
CR20140382A (es) Anticuerpos anti-lrp5 y metodos de uso
BR112016029860A2 (pt) conjugados de anticorpo antirreceptor alfa de folato (fra)-fármaco e métodos de uso dos mesmos
BR112018012313A2 (pt) composições que compreendem 15-hepe e métodos para uso das mesmas
CO2019013718A2 (es) Anticuerpos anti-trkb
AR101486A1 (es) Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso